Novel Treatment of Inflammatory Bowel Disease Informed by Science and Patient Choice
Click Here To Download Faculty Response to Questions from the Live Webcast (PDF)
Premiere Date: Wednesday, March 11, 2015This activity offers CE credit for:
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Friday, March 11, 2016
Note: Credit Is No Longer Available
 | Russell D. Cohen, MD, FACG, AGAF Professor of Medicine, Pritzker School of Medicine Director, Inflammatory Bowel Disease Center Co-Director, Advanced IBD Fellowship Program University of Chicago Medicine Chicago, IL |
 | Gary R. Lichtenstein, MD, FACP, FACG, AGAF Professor of Medicine Raymond and Ruth Perelman School of Medicine Director, Center for Inflammatory Bowel Disease Department of Medicine Division of Gastroenterololgy University Of Pennsylvania Philadelphia, PA |
 | Miguel Regueiro, MD, AGAF, FACG, FACP Chair, Digestive Disease and Surgery Chair, Department of Gastroenterology, Hepatology, and Nutrition The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology Professor, Department of Medicine Cleveland Clinic Lerner College of Medicine of Case Western Reserve University Cleveland, OH |
Inflammatory bowel disease (IBD), which consists of Crohn’s disease (CD) and ulcerative colitis (UC), is a chronic inflammatory disease of the gut, which develops because of an excessive immune response to the normal gut flora in a genetically susceptible host.1 Current therapies for IBD have not, as yet, been able to prevent the need for surgical intervention in more than 50% of IBD patients. Education to clinicians who manage patients with moderate-to-severe IBD about the immunopathophysiology of IBD and the latest available options to individualize IBD treatment can reduce the use of corticosteroids and need for hospitalizations or surgery resulting in improved quality of life for these patients.
Clinicians often treat IBD based only on diagnosis rather than considering an individual’s uniqueness, personal history, risk factors, genetics, possible immunopathogenesis, and the natural history of the disease.
Expert faculty in this CME Outfitters Live and On Demand will provide needed education about the evolving science of IBD to inform and improve treatment selection, manage side effects, and personalize the clinical approach. Faculty will address key goals to better identify patients who are likely to benefit from therapy, based on clinical criteria, but also on genotypic data.2
- Festen EA, Weersma RK. How will insights from genetics translate to clinical practice in inflammatory bowel disease? Best Pract Res Clin Gastroenterol. 2014;28(3):387-397. PMID: 24913379.
- D'Haens G, Bressler BL, Danese S, et al. Identified areas of need to enhance evidence-based inflammatory bowel disease management and patient care. Presented at: 19th Congress of ECCO; Copenhagen Denmark: February 20-22, 2014. Abstract DOP082.
This educational activity centers on the CME Outfutters Make One Change Statement. This statement is crafted from pertinent quality measures or clinical guidelines as a performance challenge to all participants. The Make One Change Statement for this activity is:
Develop an individualized treatment plan that includes regular discussions of side effects and continuously evaluates for treatment failure in individuals with IBD.
At the end of this CE activity, participants should be able to:
- Define the mechanism of disease of IBD and the role of novel agents in treatment choices.
- Describe available treatment paradigms and options for treatment failure in moderate-to-severe IBD.
- Implement a maintenance treatment plan for IBD to achieve mucosal healing and remission in patients with moderate-to-severe IBD.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Define the mechanism of disease of IBD and the role of novel agents in treatment choices.
- Review available treatment paradigms and options for treatment failure in moderate-to-severe IBD.
- Evaluate a personalized treatment plan to maintain mucosal health and remission in patients with moderate-to-severe IBD.
Supported by an educational grant from Takeda Pharmaceuticals International, Inc., U.S. Region.
Gastroenterologists, physician assistants, nurse practitioners, nurses, pharmacists, and other health care professionals who manage and counsel patients with IBD.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs)
Universal Activity Number: 0376-0000-15-005-L01-P (live programs)
0376-0000-15-005-H01-P (recorded programs)
Activity Type: knowledge-based
Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST967 (requires free account activation). Participants should review the required information: target audience, learning objectives, and disclosure information. Participants should complete the entire self-study activity and print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Cohen has disclosed that he has received research grants from Janssen Research & Development, LLC (Johnson & Johnson / Centocor). He serves as a consultant to AbbVie Inc.; Celgene Corporation; Entera Health, Inc.; Hospira, Inc.; Janssen Research & Development, LLC (Johnson & Johnson / Centocor); Prometheus Laboratories Inc.; Salix Pharmaceuticals, Inc.; Sandoz Biopharmaceuticals; Shire; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc. He is on the speakers bureau of AbbVie Inc.; Entera Health, Inc.; Salix Pharmaceuticals, Inc.; and
Shire PLC.
Dr. Lichtenstein has disclosed that he has received research grants from Ferring Pharmaceuticals; Janssen Biotech, Inc./Centocor Ortho Biotech, Inc.; Prometheus Laboratories Inc.; Salix Pharmaceuticals, Inc.; Santarus, Inc.; Shire; UCB, Inc.; and Warner Chilcotte. He serves as a consultant for AbbVie Inc.; Actavis; Alaven Pharmaceutical LLC; Ferring Pharmaceuticals; Hospira; Janssen Biotech, Inc./Centocor Ortho Biotech, Inc.; Luitpold Pharmaceuticals, Inc./American Regent, Inc.; Pfizer Inc.; Prometheus Laboratories Inc.; Salix Pharmaceuticals, Inc.; Santarus, Inc.; Schering-Plough Corporation; Shire; Takeda Pharmaceuticals U.S.A., Inc.; UCB, Inc.; Warner Chilcotte. He has received other financial or material support as Editor, Clinical Advances in Gastroenterology; Editor, Gastroenterology & Hepatology; Ironwood (CME program); Luitpold Pharmaceuticals/American Regent, Inc. (CME); SLACK, Inc. (Book royalty)
Dr. Reguerio has disclosed that he serves as a consultant to AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Shire; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc.
Kimberley Murray, RN, MS (peer reviewer) has no disclosures to report.
Frances C. Daniel, MPH (planning committee) has no disclosures to report.
Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.
Sandra Haas Binford, MAEd (planning committee) has no disclosures to report.
Disclosures have been obtained from CME Outfitters staff: No disclosures to report.
Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
CME Outfitters, LLC, the faculty, and Takeda Pharmaceuticals International, Inc., U.S. Region do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
TV-080-031115-20
